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the rise and are reaching epidemic proportions [4]. Thus efficient 
ways to treat bone injuries need to be urgently addressed. 
Regenerative medicine deals with repairing or replacing the 
damaged tissues or organs, with scaffolds, cells, and growth factors 
in any combination or individually to fully restore the injured tis-
sue’s structure and function. This combination of cells, growth fac-
tors, and scaffolds is often referred to as the tissue engineering 
triad [5] (fig. 1).
Within this field lies the branch of bone regeneration also known 
as bone tissue engineering. Bone tissue engineering is quite ad-
vanced compared to other tissue engineering fields, due to the fact 
that bone itself has a high regenerative potential since it undergoes 
a continuous remodeling and turn-over process. The classical work 
by Urist [6] back in 1965 demonstrated that bone has autoinduction 
ability, and new bone formation can be induced from injured bone 
tissue. Over the years, we now know much more about the inducers 
of bone formation which include growth factors and about the cells 
which are induced to differentiate to bone cells. Osteoblasts, the 
bone-forming cells are derived from the mesenchymal lineage; 
therefore mesenchymal stromal cells (MSCs; also known as mesen-
chymal stem cells)  harvested from sources like bone marrow or fat 
tissue are widely used in bone regeneration. These cells dock on the 
scaffolds, which are osteoconductive, and then the growth factors 
induce these osteogenic cells leading to the ingrowth of bone into 
3D-structures, preferentially leading to creeping substitution. 
Bone autograft is the gold standard scaffold and is still consid-
ered the safest and the most effective treatment of large bone de-
fects. This uses patient’s own autologous bone, which provides a 
natural substrate for new osteogenic cells to grow into the graft 
enabling the healing and re-modeling of the injured bone [7]. 
However, a major drawback with autografts involves pain and in-
fection around the donor bone area, the limitation in donor bone 
volume (only 20 cm3) and incomplete integration of the grafted 
bone [8]. Thus bone tissue engineering seems to be a promising 
therapeutic alternative as it would drastically eradicate the pain 
and overcome the limitation caused by autografts.
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Summary
2500 years ago, Hippocrates realized that bone can heal 
without scaring. The natural healing potential of bone is, 
however, restricted to small defects. Extended bone de-
fects caused by trauma or during tumor resections still 
pose a huge problem in orthopedics and cranio-maxillo-
facial surgery. Bone tissue engineering strategies using 
stem cells, growth factors, and scaffolds could overcome 
the problems with the treatment of extended bone de-
fects. In this review, we give a short overview on bone 
tissue engineering with emphasis on the use of adipose 
tissue-derived stem cells and small molecules. 
© 2016 S. Karger GmbH, Freiburg
Introduction
Bone tissue has a unique ability to remodel and heal naturally 
without leaving any scar; however, 10% of large bone defects can-
not heal naturally, and this requires an urgent need of either sur-
gery or bone transplantation [1]. It has been reported that segmen-
tal bone defects which are most commonly found in the tibia may 
result in amputation if structural integrity of the bone cannot be 
restored and maintained [2]. 
Bone is the most commonly transplanted tissue, and about 1 
million patients undergo surgical bone reconstruction annually in 
Europe. In the European Union, 22 million women and 5.5 million 
men are estimated to have osteoporosis; and 3.5 million new fragil-
ity fractures were sustained [3]. With the rise in life expectancy, the 
incidences of bone-related injuries in an ageing population are on 
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Presently, numerous materials are being investigated for their 
ability to function as scaffolds which have the characteristic to 
mimic the composition of bone (i.e. calcium phosphate and colla-
gen). Most materials can be chemically treated or biologically func-
tionalized with peptides to enhance their osteoconductivity, degra-
dability, and angiogenic response. More importantly, the scaffold 
should provide a proper environment for homing, proliferation, 
differentiation, and migration of osteogenic and other cells associ-
ated with bone regeneration.
MSCs derived from bone marrow (mostly from iliac-crest aspi-
rates) are commonly used in bone tissue engineering. MSC-based 
cell therapy has the potential to promote bone regeneration and 
has been well studied [9]. However, the stem cells originating from 
other sources, such as periosteum-derived or adipose tissue-de-
rived stem cells (ADSCs), can also support bone regeneration [7]. 
These cells express the classical MSC markers, have the ability to 
differentiate into osteogenic cells, and contribute extensively to 
bone regeneration in vivo. Bone tissue engineering thus involves 
isolation of the MSCs and their in vitro culturing on biomaterials 
to obtain a proper colonization and differentiation of the cells so 
that the biomaterial-cell construct could then be implanted in the 
injured area of the bone.
Various growth factors are being investigated to make the bio-
materials osteoinductive. Bone morphogenetic proteins (BMPs), 
members of the TGF-β superfamily, are natural and the most com-
mon growth factors responsible for osteoinduction, which is the 
differentiation of MSCs to bone forming cells and are able to in-
duce bone formation even at ectopic sites. Notably BMP-2 has 
shown to be highly osteoinductive and is currently approved for 
spinal fusion and open tibia fractures, although application of 
high-doses of BMP alone has proven not to be safe as initially 
 believed [10]. Bone vascularization is integral to the bone regenera-
tion process where angiogenic growth factors, such as vascular 
 endothelial growth factor (VEGF), are involved. For effective bone 
vascularization and regeneration, the crosstalk between endothelial 
and osteogenic progenitor cells is essential which involves a multi-
tude of signaling growth factors such as VEGF, fibroblast growth 
factor (FGF), the transforming growth factor (TGF) superfamily 
(BMP-2, BMP-7, BMP-9, TGF-β) and receptor activator of nuclear 
factor kappa ligand (RANKL) [11]. These growth factors released 
by different cells trigger bone formation leading to effective bone 
regeneration.
In this review, we would look at the scaffolds and the cells. In 
particular, this review seeks to discuss the ability of ADSCs, which 
could differentiate into osteogenic cells. We also discuss the role 
of small molecules and their contribution in enabling bone 
regeneration.
Scaffolds 
Scaffolds essentially resemble a bioreactor. They act as an osteo-
conductive template for bone tissue formation where osteogenic 
progenitor cells (generally MSCs) are seeded in vitro with or with-
out growth factors and then implanted into an injured area or they 
could be implanted directly into the injured site for bone regenera-
tion. Moreover, scaffolds provide the appropriate homing space for 
transplanted cells and help retain the endogenous cells together 
with appropriate mechanical cues and biological triggers.
To be suitable as a scaffold, a material needs to fulfill the follow-
ing requirements [2]:
– Biocompatibility: Cells should adhere to scaffolds, function and 
metabolize normally, proliferate, and migrate. Scaffolds should 
give rise to minimal immunologic reaction.
– Biodegradability: Scaffold should eventually be replaced by 
body’s own cells. Moreover, the by-products of the degraded 
scaffold should be non-toxic, and the body should be able to 
clear it up without much interference with other organs.
Fig. 1. Core components of tissue engineering. 
The scaffold, cells, and growth factors are required 
for the development of tissue regeneration, and 
these components are dependent on each other for 
effective tissue healing.
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– Mechanical integrity: Scaffold should possess the desired 
 mechanical strength to withstand the stress from the time of 
implantation to the completion of bone regeneration. More-
over, the scaffold should match its mechanical property to the 
injured bone where it would be implanted. 
– Architecture: Scaffolds should be able to support cell infiltration 
and vascularization. They should have optimal pore size, an 
 interconnected pore structure, and high porosity for cells, nu-
trients and waste products passage. They should have the 
strength to bear pressure and mechanical stress.
– Manufacturing technology: Scaffold should be easily manufac-
tured and be cost-effective. They should be scalable, and adjust-
ments in scaffold technology should be easy to perform.
Scaffolds can be fabricated with biomaterials. The concept of a 
biomaterial has been defined as ‘a substance that has been engi-
neered to take a form which is used to direct, by control of interac-
tions with components of living systems, the course of any thera-
peutic or diagnostic procedure’ [12]. Presently, mainly 4 individual 
groups of biomaterials are being used in the fabrication of scaf-
folds. These are i) ceramics such as calcium phosphate, hy-
droxyapatite (HA), and tri-calcium phosphate (TCP); ii) synthetic 
polymers such as polystyrene, poly-l-lactic acid (PLLA), polycapro-
lactone (PCL), and polyglycolic acid; iii) natural polymers such as 
collagen, glycosaminoglycan, chitosan, hyaluronic acid, fibrin, and 
elastin; and iv) metals like titanium and magnesium. 
A list of these biomaterials along with their advantages and dis-
advantages is presented in table 1 [2, 5]. Since these biomaterials 
have their characteristic advantages and disadvantages, hence the 
development of composite scaffolds is gaining more interest. Com-
posite scaffolds are in general a combination of biomaterials. For 
example, a combination of ceramic and polymer scaffold [13] or a 
combination of ceramic, synthetic polymer and natural polymer 
biomaterials [14]. Since natural biomaterials lack the required me-
chanical strength, a collagen and nano-hydroxyapatite-based scaf-
fold with adequate mechanical strength having high porosity and 
interconnected pore structure is a valid model [15]. Such a com-
posite scaffold facilitates improved cellular infiltration and vascu-
larization. Although composite scaffolds have shown some prom-
ise, they might contain components which are not found naturally 
and hence they have associated problems with biocompatibility 
and immunologic response.
Recent research in bone tissue engineering has also investigated 
the development of three dimensional (3D) scaffolds resembling 
more the natural situation. In this regard, additive manufacturing 
(AM), the computer-directed process of 3D layer-by-layer model 
fabrication has seen some interesting development [2]. This 3D 
scaffold development technology offers the potential for fabrica-
tion of implants of exquisite complexity and preciseness that could 
range from permanent to biodegradable and that could be im-
planted at the injured bone site. Additive manufacturing enables 
personalized treatment, which could be a great benefit for the 
treatment of special types of bone defects.
Bone Marrow Cells 
MSCs, originally also called bone marrow (BM) stromal cells, 
were for the first time isolated from bone marrow by Friedenstein 
et al. [16], in 1976 and has since then been considered the progeni-
tor cells for skeletal tissues. MSCs are defined as plastic culture 
 adhesive cells with an inherent characteristic to be colonogenic and 
multipotent and can differentiate into several mesodermal cell line-
ages including osteoblasts, chondrocytes, adipocytes, tenocytes, 
and myoblasts. MSCs are typically identified by their expression of 
CD90, CD105, CD73 and CD146, and the absence of CD45, CD34, 
CD14, CD11b, CD79a, CD19 and HLA-DR [17]. A common 
source for aspirating the MSCs is the iliac crest. These aspirated 
cells are then grown and expanded in vitro and then seeded on 
 selected scaffolds and cultured with the aim of having a homogene-
ous distribution of cells that are metabolically active. The evalua-
Table 1. Advantages and disadvantages of various biomaterials
Biomaterial Advantages Disadvantages
Ceramics Widely used for bone regeneration and display good bone integration
High mechanical stiffness
Excellent biocompatible
Enhance osteoblast differentiation and proliferation
Very low elasticity
Hard brittle surface
Lack remodeling ability
Slow rate of degradation
Synthetic polymers Fabricated with tailored architecture
Controlled degradation 
Risk of rejection due to reduced bioactivity
The degradation by-products could cause cellular damage 
and tissue necrosis
Natural polymers Biologically active
Promote excellent cellular adhesion
Biodegradable
Minimal adverse immunological response
Difficulty in fabricating scaffold homogenously and  
reproducibly
Poor mechanical properties
Metals High mechanical strength
High level of osteointegration 
Allow personalized manufacturing by laser sintering
The surface of titanium can be osteoconductive
Titanium is not degradable
Magnesium degrades but forms hydrogen gas
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tion of the osteogenic potential of the cells inside the scaffold can 
be made indirectly, by measuring osteo-specific secreted proteins, 
such as osteocalcin, or by performing the bone-specific gene ex-
pressional analysis [7]. 
There are many parameters that contribute towards the housing 
of the MSCs in the scaffolds. Firstly, the MSCs should adhere prop-
erly to the scaffold. Secondly, the cell/biomaterial volume ratio is 
highly critical. Thirdly, high porosity and permeability of scaffolds 
could help the MSCs to have a uniform cell invasion, in vivo tissue 
ingrowth, vascularization, and osteogenesis. Fourthly, there should 
be a high degree of freedom for tissue ingrowth through intergran-
ular spaces between particulate scaffolds [7]. 
Some studies have reported that the effectiveness of cell-based 
therapy at the site of the injury is inhibitory/detrimental to tissue 
development. However, delayed injection of MSCs after the set-
tling of initial acute-phase inflammation has shown enhanced re-
pair of damaged tissue compared to ‘time-of-trauma’ application. 
Moreover, enhanced reparation is observed when cells are intro-
duced subcutaneously, intravenously as well as directly to the 
wound site [18]. Due to regulatory issues, fracture fixation, stem 
cell harvesting, and application should be performed during a sin-
gle operation.
Bioceramic scaffold when treated with fresh autologous bone 
marrow aspirate that is a rich source of MSCs and growth factors 
has been shown to be as effective as autologous bone grafting in 
spinal fusion procedures [19]. Even though osteogenic cells are 
 important for bone regeneration, some studies have shown that 
 ceramic bone substitutes alone or calcium phosphate cement ap-
plication can heal adequately without the need of bone marrow 
 aspirate to treat benign bone cavity or tibial plateau fractures [20, 
21]. Thus the kind of biomaterial and the progenitor cells to be 
used may probably be dependent on the type and location of the 
bone defect.
Adipose Tissue-Derived Stem Cells
Due to its abundance, ease to harvest, minimal morbidity and 
high colonogenic ability, adipose tissue is a convenient source for 
isolation and culturing of ADSCs that could be used in regenera-
tive medicine and tissue engineering [22, 23]. ADSCs are a type of 
MSCs, and they possess robust osteogenic potency. ADSCs can be 
maintained longer in culture and possess a higher proliferation ca-
pacity compared to bone marrow-derived MSCs [24]. The stromal 
vascular fraction (SVF) of the adipose tissue is generally used for 
isolation of the progenitor cells that could be differentiated to both 
osteogenic and endothelial cells [22] both of which are important 
for bone regeneration. 
The white adipose tissue, which is the main adipose tissue in 
the human body, is an interesting reservoir for stem cells. Within 
the white adipose tissue, more ADSCs reside in the subcutaneous 
depots compared with the depots of visceral fat. ADSCs have also 
been reported in brown fat depots but not much is known about it 
[24]. The secretome of the ADSCs contains different endocrine 
factors (adipokines) with bone remodeling activity. In particular, 
VEGF present in the secretome contributes greatly in the repair of 
fractures or bone defects. Moreover, VEGF triggers angiogenesis, 
which is important for bone regeneration. However, much more 
research needs to be performed on the in vivo bone-forming po-
tential of ADSCs and their utilization in bone tissue engineering 
[22]. 
Although the MSCs from bone marrow and adipose tissue are 
considered quite similar, there is a growing appreciation of possi-
ble innate differences in their biology and response to growth fac-
tors. Moreover, microarray analysis indicated that bone marrow-
derived MSCs and ADSCs demonstrate differentially expressed 
genes [25]. Studies have shown that their osteogenic response to 
platelet-derived growth factor BB (PDGF-BB) is markedly differ-
ent. The bone marrow-derived MSCs had no effect to PDGF-BB 
while ADSCs exhibited enhanced mineralization, produced more 
calcium per cell, and upregulated osteogenic genes in response to 
physiological concentrations of PDGF-BB; and this effect was 
 mediated via its receptor PDGFR-β [26]. 
Materials using fabricated poly(propylene fumarate)-based 3D 
scaffolds with an ability to slowly release BMP-2 in the presence of 
human ADSCs have shown to be highly osteogenic and have the 
potential to be used as an effective reconstruction tool for cranial 
defects [27]. These authors used biodegradable poly lactic-co-gly-
colic acid (PLGA) microspheres containing BMP-2 to create a 
drug-releasing scaffold and this was shown to be effective for treat-
ing extended bony defects [27]. 
Controlled delivery of BMP-2 from gelatin hydrogel had a sig-
nificant effect on human ADSC osteogenic differentiation com-
pared to exogenous BMP-2. Moreover, lower dose of BMP-2 had a 
striking effect [28]. Co-expression of BMP-2 and Runx2 in ADSCs 
caused significantly increased bone regeneration [29]. Similarly, 
ADSCs expressing both LIM-1 and HIF-1α had elevated levels of 
BMP-2 and Runx2 and increased osteogenesis in vivo compared 
with either LIM-1 or HIF-1α alone [30]. 
Studies have been performed which showed the advantage of 
using ADSCs in combination with biomimetic scaffold. An in 
vitro study using porcine ADSCs have shown their high osteo-
genic differentiation rate on polycaprolactone-β-tricalcium phos-
phate-collagen scaffolds. This was indicated by high alkaline phos-
phatase (ALP) activity, osteocalcin expression, and mineralization 
[31]. Using akermanite-based scaffolds, Zanetti and colleagues 
[32] have shown that ADSCs cultured for 21 days in osteogenic 
medium before seeding them on the scaffold have greater calcium 
deposition and osteocalcin expression and low IL-6 expression, 
compared with cells seeded on polycaprolactone-β-tricalcium 
phosphate. In an interesting study by Fröhlich and colleagues [33], 
ADSCs seeded on decellularized native bone scaffolds which pro-
vided the necessary structural and mechanical environment for 
osteogenic differentiation showed increased construct cellularity 
and elevated amounts of bone matrix components (collagen, bone 
sialoprotein, and osteopontin). This was achieved in 5 weeks after 
the addition of osteogenic supplements (dexamethasone, sodium-
β-glycerophosphate, and ascorbic acid-2-phosphate) to culture 
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medium. In table  2, we list some of the studies performed with 
ADSCs in animal models and the type of scaffold used. Most of 
these studies suggest that ADSCs from human or murine sources 
in combination with different scaffolds could lead to effective 
 osteogenesis and bone regeneration.
Recently, Silva and colleagues [34] demonstrated that human 
ADSCs differentiate towards the osteogenic phenotype when cul-
tured in a bioactive glass scaffold as indicated by significant in-
crease in cell proliferation and viability, along with increased ALP 
activity and the expression of osteospecific proteins such as osteoc-
alcin and osteopontin. One of the major limitations of such cellular 
growth on scaffolds is the lack of angiogenesis. However, implanta-
tion of porous 3D constructs cultured with cells from stromal 
 vascular fraction (SVF) of adipose tissue into nude mice were able 
to generate bone tissue and fully functional blood vessels [35], pos-
sibly due to the presence of human osteoblast and endothelial line-
age cells in the SVF [36].
It is noteworthy that successful results, in terms of bone heal-
ing, have been achieved in different animal models, using either 
undifferentiated ADSCs or uncultured SVF, showing the huge po-
tential of these progenitor cells in bone healing and formation 
[37]. Despite an increasing number of scientific data on ADSCs 
and their ability to repair and regenerate bone in vivo, to date 
there are very limited controlled clinical trials which have been 
performed with ADSCs in patients with bone-related disorders. 
Nevertheless, some successful results have been obtained in dis-
tinct trials where autologous ADSCs derived from anterior ab-
dominal wall, when seeded onto either bioactive glass or 
β-tricalcium phosphate in combination with BMP-2, resulted in 
cranio-maxillofacial bone reconstruction [38, 39]. More, con-
trolled trials definitely need to be carried out either with ADSCs or 
with adipose tissue-derived SVF. 
Growth Factors 
Growth factors are small proteins that have the ability to acti-
vate and induce the regeneration of new tissue to replace injured 
and damaged tissue. For this reason, these factors are being ex-
ploited in the field of bone tissue engineering. Growth factors, such 
as BMPs, stimulate the cells via the cell surface receptors and acti-
vate downstream signaling cascades causing cellular proliferation 
and/or differentiation.
BMPs regulate bone formation during skeletal development and 
play an important role in bone development, remodeling, and re-
pair. BMPs are members of the transforming growth factor-β 
 superfamily of proteins and maintain bone mass during postnatal 
growth and participate actively in bone repair [40]. BMP-2 has 
been shown to maintain the osteoprogenitor cells, promote 
 differentiation to osteoblasts, and is critical in bone healing [41]. 
There have been significant efforts to deliver BMPs in an efficient 
manner to regenerate bone, and commercial Food and Drug 
Administration(FDA)-approved recombinant (rh) BMP products 
are available such as OP-1® (BMP-7; Olympus Biotech, Lyon, 
France) or BMP-2 (infuse Bone Graft; Medtronic, Minneapolis, 
MN, USA). Pre-clinical and clinical studies using BMPs have been 
clearly successful [42, 43]. As a result, FDA clearance has been 
granted to BMP-2 and BMP-7 for specific clinical applications such 
as fracture healing, long bone non-unions, spinal fusion, and peri-
odontal as well as dental regeneration procedures [40].
However, there are certain limitations associated with the use 
and production of BMPs or other protein therapeutics. i) Increased 
dosage of BMP-2 has adverse health side effects. ii) rh BMPs are 
expensive and could be a burden on the patient. iii) rh BMPs may 
have traces of biologically active impurities. iv) rh BMPs could 
elicit undesirable immune responses. To overcome these limita-
tions, a possible strategy would be to reduce the effective amount 
of rh BMP in the clinic and to replace them with other new mole-
cules or to have a system of co-delivery with an enhancer of BMP’s 
activity. These new molecules should have all the required bone 
regeneration qualities like BMP, be less expensive and easily avail-
able, have minimal to no side effects, have no contaminants, be 
 stable, and should not trigger immune response. 
Other molecules such as short peptides can also contribute 
 towards efficient bone regeneration. Short peptides are segments of 
therapeutic proteins and have been investigated widely for tissue 
Table 2. The use of ADSCs together with various scaffolds in in vivo animal models 
Animal model Scaffold Result Reference
hADSCs subcutaneously in BalB/c nude mice polylacticcoglycolic acid (PLGA) with  
bone forming peptide and poly-  
dopamine film
superior ectopic bone formation [55]
hADSCs mixed with porcine atelocollagen in  
BalB/c nude mice calvarium
nanohydroxyapatite osteogenesis of transplanted ADSCs and  
thick new bone formation
[56]
Mouse ADSCs in femoral segmental critical-sized  
defect in mouse 
sterile cancellous bone new bone formation not only at the bony  
edges but also inside the scaffold
[57]
Rat miR-135 transduced ADSCs in critical-sized  
calvarial defect in rats
poly(sebacoyl diglyceride) new bone formation [58]
Rat ADSCs in rotator cuff model in rat multilayered PLGA nanofibers with  
fibrin matrix with BMP2
impaired tendon to bone healing with  
BMP2
[59]
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engineering purposes. In comparison to the growth factors such as 
BMPs, the short peptides exhibit a smaller size. They are synthe-
sized in the laboratory and contain the active sequence of the par-
ent molecule. They are more stable and less immunogenic due to 
their small size. For example, the BMP-derived short peptides are 
quiet stable, and they interact with BMPR-I and II which triggers 
the downstream signaling pathways [44]. Positive in vitro and in 
vivo results have been obtained with the short peptides, and these 
peptides have shown to have osteogenic ability [40, 45, 46]. Other 
short peptides have been synthesized based on the active sequence 
of the parent proteins such as collagen type 1, bone sialoprotein, 
osteopontin and osteogenic growth peptide. These works have 
been discussed well in recent reviews by Balmayor [40] and by 
Maia et al. [44].
Another class of emerging molecules is the small osteoinductive 
molecules that act as enhancer of growth factors. These small mol-
ecules have recently emerged as promising candidates for tissue 
regeneration. Due to their small size, they display low immuno-
genicity. These molecules could permeate or diffuse easily across 
the cell membrane, triggering the downstream signaling cascade. 
These molecules have been found to activate BMP signaling, stim-
ulate the hedgehog (Hh) pathway or influence the Wnt/beta-
catenin or cyclic adenosine monophosphate/ protein kinase A 
(cAMP/PKA) signaling pathways.
Dexamethasone, phenamil, oxysterols, purmorphasmine, fin-
golimod, lovastatin, atrovastatin, rosuvastatin, and simvastatin are 
examples for small osteogenic molecules reported thus far [40]. All 
these molecules display osteogenic properties in in vitro or in vivo 
models and have shown to increase the expression of bone-related 
genes, bone mineralization, and new bone formations. Moreover, 
these compounds have an additive effect when used in combina-
tion with BMPs. For example, phenamil has an additive effect with 
BMP-2 and BMP-7 in osteoblast differentiation and mineraliza-
tion [47].
In our laboratory, we have shown that the small molecule N-
methyl pyrrolidone (NMP), which has a very low molecular 
weight (99.1 g/mol) and is soluble both in water and organic sol-
vent, could enhance BMP-2 action [48]. NMP is a FDA-approved 
injectable pharmaceutical excipient and is safe if used within the 
prescribed doses [49]. NMP has been shown to activate the bone-
forming activities of osteoblasts and decrease bone resorption of 
osteoclasts [48, 50]. An in vivo study using rabbit calvarial defect 
showed significantly higher bone regeneration with NMP by in-
creasing the activity of the natural locally deposited autologous 
BMP [48]. NMP at concentrations between 1 and 5 mmol/l en-
hances BMP activity two to eight times and is most efficient at low 
BMP concentrations. Using an in situ forming implants (ISFI) sys-
tem; we developed a slow and sustained double delivery mecha-
nism for rh BMP-2 and its enhancer NMP. Using the dual delivery 
ISFI system, rh BMP-2 and NMP were shown to bridge the critical 
size defect in the calvarial bone and aid in bone regeneration [51]. 
Thus enhancer small molecules like NMP could replace the high 
dose of BMPs and activate the action of the growth factors for 
 efficient osteogenesis.
Vascularization
As for all tissue engineering approaches, vascularization is a 
limiting factor. For bone tissue engineering this aspect was re-
viewed recently [52] and can be facilitated on the level of growth 
factors or cell combinations. BMP-2, a key growth factor for bone 
tissue engineering, was shown to stimulate proliferation and tube 
formation of human aortic endothelial cells [53]. Such effects could 
also be of an indirect nature by induction of the angiogenic factor 
VEGF-A [54]. Double delivery of BMPs and VEGF was shown to 
increase bone formation even further [55]. In larger animals (bea-
gles), the timing of the release of the individual factors had no ef-
fect on the orthotopic site. At an ectopic site, fast BMP release was 
superior in terms of new bone formation, and addition of VEGF 
had no effect [56]. 
Cellular strategies to promote vascularization in tissue engi-
neering approaches have been reviewed recently [57], and the pref-
erential use of pericytes have been highlighted [58]. The use and 
delivery of a combination of MSCs for bone formation and en-
dothelial cells to form a microcapillary-like network was success-
fully realized by a two-stage seeding protocol to illustrate that clini-
cally relevant progenitor sources can serve to generate highly func-
tional microvascular networks for bone tissue engineering [59]. 
Taking together, by the combination of growth factors and dif-
ferent cell types, bone tissue engineering gets more and more com-
plex and academic instead of clinically applicable to justify the ef-
forts and costs for a wide range of patients, especially when consid-
ering that in the clinic autografts and vascularized bone grafts are 
successfully used since decades [60] and in direct competition to 
the use of engineered bone. In this context, a new strategy based on 
the avascular cartilage intermediate appears very promising for 
translation into the clinic since it recapitulates natural embryonic 
bone formation by endochondral ossification and is based on 
MSCs only [61].    
Bone Regeneration: Challenges
Even though much work has been done in the field of bone tis-
sue engineering, we could still improve our present understanding 
about scaffolds, cells, and growth factors. Here is a list of some of 
the challenges that we face and that need to be addressed:
– Tissue hypoxia: A key challenge in the clinical application of 
cell-based tissue-engineered bone implants is the poor diffu-
sion of oxygen into avascular tissue [62]. Due to improper oxy-
gen diffusion the bone regeneration is not efficient, in particular 
due to improper angiogenesis. Therefore, more studies investi-
gating the ways to overcome tissue hypoxia should be per-
formed.
– Improper angiogenesis: Therapeutic targeting of angiogenesis to 
treat non-healing bone defects will be essential for improved 
clinical skeletal outcomes. Treatments with erythropoietin 
(EPO) showed to have a good effect given the potential of EPO 
to induce cartilaginous callus formation and angiogenesis, re-
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sulting in enhanced endochondral ossification. Creation of bio-
engineered heterotrophic bone around new blood vessels as 
suggested by Cai and colleagues [55] and altering the levels of 
growth factors such as VEGF and BMP-2 to modulate bone 
 repair is an interesting suggestion to enhance bone augmenta-
tion. The development of new vascular ingrowth therapies will 
definitely aid in fastening the repair of bone damage.
– Optimizing scaffolds: Future scaffolds should match the me-
chanical characteristics of bone. They should be non-immuno-
genic and biodegradable, and the degradation by-products 
should be cleared by the body without complications.
– Optimizing growth factors: At high doses, growth factors can 
result in adverse side effects such as soft tissue inflammation 
and swelling. However, it is probable that when used in reduced 
dose in combination with small chemical molecules (like NMP) 
it may stimulate the bone forming potential of the implanted 
cells, but the clinical evidence is lacking. Alternatively, the use 
of growth factors can be restricted to the pre-implantation cell 
expansion phase in order to enhance the regenerative potency 
of the implanted MSCs and thereby prevent possible side effects 
caused by in vivo application of growth factors [63].
– Translating laboratory results to clinical trials: Many of the in 
vitro techniques fail to mimic the cellular, molecular, physio-
logical, and biomechanical intricacies present in the whole or-
ganism level. To mimic these, there is a need to utilize advanced 
in vivo approaches.
Moreover, each in vivo model has an inherent magnitude of fac-
tors that influence the appropriate animal use. While current tech-
nological developments in the biomaterials field create an exciting 
environment enabling further rapid progress, clinical translation is 
still a challenge also from the regulatory point of view. The thera-
peutic success of clinically relevant regenerative implants will 
largely depend on how the implanted cells are adapted to react to 
the hostile and hypoxic host environment into which they are 
placed.
In spite of all the challenges and optimizations that need to be 
addressed, bone tissue engineering is an expansive field, and new 
combination approaches are being developed continuously. The 
goal to deliver effective and economical bone regeneration thera-
peutic tools and techniques should be the utmost priority to reduce 
bone-related injuries and diseases. 
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